Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 78Neoplasms 69Prostatic Neoplasms 51Colorectal Neoplasms 45Lung Neoplasms 39Carcinoma, Non-Small-Cell Lung 28Hematologic Neoplasms 22Pancreatic Neoplasms 21Neoplasm Metastasis 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 15Ovarian Neoplasms 15Multiple Myeloma 15Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Motor Activity 11Leukemia, Myeloid, Acute 11Glioblastoma 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Gastrointestinal Neoplasms 9Colonic Neoplasms 9Melanoma 8Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Esophageal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bilateral Breast Carcinoma × Standard of Care × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡